Genomma Lab Internacional SAB de CV (GNMLF) recently announced a dividend of $0.2 per share, payable on 2023-12-27, with the ex-dividend date set for 2023-12-22. As investors look forward to this ...

Genomma Lab Internacional, S.A.B. de C.V.(BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international ...

Charisse Winecki, head of the U.S. general market at Genomma Lab, sees an opportunity for Bufferin to gain market share among consumers. She talked about the reintroduction of the brand into the ...

Like-for-like ("LFL") sales: when adjusted into constant currency and excluding the hyperinflationary subsidiary, sales increased by 9.7% reflecting a double-digit increase in six out of nine core ...

HOUSTON--(BUSINESS WIRE)--As consumers continue to adapt their behaviors due to the COVID-19 pandemic, offering quality and known products that can help them with their day-to-day life in the “new ...

MEXICO CITY, Oct. 22, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the third quarter of 2025. All figures ...

Genomma Lab Internacional SAB de CV Class B ((MX:LABB)) has held its Q3 earnings call. Read on for the main highlights of the call. Take advantage of TipRanks Premium at 50% off! Unlock powerful ...

Net sales: 6.4% increase reflecting healthy growth across regions, sales recovery in Argentina and a favorable FX environment for Genomma's ex-Mexico operations. 78% of sales grew above inflation and ...

Net sales: +5.0% increase reflecting strong Suerox sales growth across markets, primarily offset by a weaker-than-expected flu season and related market share loss of Genomma cough & cold brands in ...

(2) EBITDA defined as operating income before depreciation and amortization Net Sales: Like-for-like sales declined -3.9%, reflecting weak consumption in Mexico and disruptions in the U.S. Hispanic ...